Przewidywanie ciężkości COVID-19
Przewidywanie ciężkości COVID-19 za pomocą swoistego przeciwciała nukleokapsydowego i wskaźnika czynnika ryzyka choroby
Efficient strategies for predicting COVID-19 illness trajectories are urgently wanted. Right here, enzyme-linked immunosorbent assay (ELISA) and coronavirus antigen microarray (COVAM) evaluation mapped antibody epitopes within the plasma of COVID-19 sufferers (n = 86) experiencing a variety of illness states. The experiments recognized antibodies to a 21-residue epitope from nucleocapsid (termed Ep9) related to extreme illness, together with admission to the intensive care unit (ICU), requirement for ventilators, or demise.
Importantly, anti-Ep9 antibodies will be detected inside 6 days post-symptom onset and generally inside 1 day. Moreover, anti-Ep9 antibodies correlate with varied comorbidities and hallmarks of immune hyperactivity. We introduce a simple-to-calculate, illness threat issue rating to quantitate every affected person’s comorbidities and age. For sufferers with anti-Ep9 antibodies, scores above 3.Zero predict extra extreme illness outcomes with a 13.42 chance ratio (96.7% specificity).
The outcomes lay the groundwork for a brand new sort of COVID-19 prognostic to permit early identification and triage of high-risk sufferers. Such info might information more practical therapeutic intervention.IMPORTANCE The COVID-19 pandemic has resulted in over two million deaths worldwide. Regardless of efforts to struggle the virus, the illness continues to overwhelm hospitals with severely unwell sufferers.
Prognosis of COVID-19 is instantly completed by a mess of dependable testing platforms; nonetheless, prognostic prediction stays elusive. To this finish, we recognized a brief epitope from the SARS-CoV-2 nucleocapsid protein and likewise a illness threat issue rating primarily based upon comorbidities and age. The presence of antibodies particularly binding to this epitope plus a rating cutoff can predict extreme COVID-19 outcomes with 96.7% specificity.
Human IGF-BP4 Recombinant Protein |
|||
| 100-200 | ReliaTech | 20 µg | EUR 196.35 |
|
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 26.1 kDa protein consisting of 238 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. |
|||
Human IGF-BP4 Recombinant Protein |
|||
| 100-200S | ReliaTech | 5 µg | EUR 92.4 |
|
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 26.1 kDa protein consisting of 238 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. |
|||
Recombinant Human IGF-BP4 Protein |
|||
| PROTP22692-1 | BosterBio | 20ug | EUR 380.4 |
|
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 25.8 kDa protein consisting of 237 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. *Manufactured using (BTI-Tn-5B1-4) cells under license from the Boyce Thompson Institute for Plant Research, Inc. |
|||
Human IGF-BP4 Recombinant Protein Lyophilized |
|||
| IHUIGFBP4RLY5UG | Innovative research | each | EUR 341 |
|
Description: Human IGF-BP4 Recombinant Protein Lyophilized |
|||
Human IGF-BP4 Recombinant Protein Lyophilized |
|||
| MBS8432291-INQUIRE | MyBiosource | INQUIRE | Ask for price |
IGF-BP4 Recombinant Protein |
|||
| 40-318-0005mg | ProSci | 0.005 mg | EUR 311.1 |
|
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 25.8 kDa protein consisting of 237 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. |
|||
IGF-BP4 Recombinant Protein |
|||
| 40-318-002mg | ProSci | 0.02 mg | EUR 437.1 |
|
Description: IGF-BPs control the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP4 is the major IGF-BP produced by osteoblasts, and is also found in the epidermis, ovarian follicles, and other tissues. IGF-BP4 inhibits the activity of IGF-I and IGF-II by binding in a manner that results in the formation of complexes with reduced ability to signal through cell surface IGF receptors. IGF-BP4 can inhibit the growth of chick pelvis cartilage and HT29 colon adenocarcinoma cells by blocking the mitogenic actions of IGFs, and has also been shown to reduce colony formation by colorectal cancer cells via an IGF independent pathway. The biological effects of IGF-BP4 can be regulated by Pregnancy Associated Plasma Protein A (PAPP-A), which reduces IGF-BP4/IGF binding affinity by proteolytically cleaving IGF-BP4. The modulation of IGF-BP4 activity by PAPP-A is an important component in the regulation of ovarian folliculogenesis and in the growth inhibition of responding ovarian cancer cells. Recombinant human IGF-BP4 is a 25.8 kDa protein consisting of 237 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. |
|||
Recombinant Human IGF BP3 |
|||
| HEGFP-0903 | Cyagen | 5ug | Ask for price |
Recombinant Human IGF BP5 |
|||
| HEGFP-0905 | Cyagen | 5ug | Ask for price |
Recombinant Human IGF BP7 |
|||
| HEGFP-0907 | Cyagen | 5ug | Ask for price |
human anti-human IGF-1 mAb(6E) |
|||
| E4A09K04-6E | EnoGene | 50ug | EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
human anti-human IGF-1 mAb(8D) |
|||
| E4A09K04-8D | EnoGene | 50ug | EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
Rabbit Anti Human RIPK1 Monoclonal Clone IGF-18 |
|||
| IRBAHURIPK1IGF18C100UL | Innovative research | each | EUR 496 |
|
Description: Rabbit Anti Human RIPK1 Monoclonal Clone IGF-18 |
|||
Human IGF-BP7 |
|||
| MBS691503-0005mg | MyBiosource | 0.005mg | EUR 300 |
Human IGF-BP7 |
|||
| MBS691503-0025mg | MyBiosource | 0.025mg | EUR 450 |
Human IGF-BP7 |
|||
| MBS691503-5x0025mg | MyBiosource | 5x0.025mg | EUR 1725 |
Human IGF-BP6 |
|||
| MBS691832-0005mg | MyBiosource | 0.005mg | EUR 300 |
Human IGF-BP6 |
|||
| MBS691832-002mg | MyBiosource | 0.02mg | EUR 450 |
Human IGF-BP6 |
|||
| MBS691832-5x002mg | MyBiosource | 5x0.02mg | EUR 1725 |
Human IGF-BP3 |
|||
| MBS692057-0005mg | MyBiosource | 0.005mg | EUR 300 |
Human IGF-BP3 |
|||
| MBS692057-0025mg | MyBiosource | 0.025mg | EUR 450 |
Human IGF-BP3 |
|||
| MBS692057-5x0025mg | MyBiosource | 5x0.025mg | EUR 1725 |
Human IGF-BP2 |
|||
| MBS692085-0005mg | MyBiosource | 0.005mg | EUR 300 |
Human IGF-BP2 |
|||
| MBS692085-002mg | MyBiosource | 0.02mg | EUR 450 |
Human IGF-BP2 |
|||
| MBS692085-5x002mg | MyBiosource | 5x0.02mg | EUR 1725 |
Human IGF-BP1 |
|||
| MBS692092-0005mg | MyBiosource | 0.005mg | EUR 300 |
Human IGF-BP1 |
|||
| MBS692092-0025mg | MyBiosource | 0.025mg | EUR 450 |
Human IGF-BP1 |
|||
| MBS692092-5x0025mg | MyBiosource | 5x0.025mg | EUR 1725 |
Human IGF-BP5 |
|||
| MBS692152-0005mg | MyBiosource | 0.005mg | EUR 300 |
Human IGF-BP5 |
|||
| MBS692152-0025mg | MyBiosource | 0.025mg | EUR 450 |
Human IGF-BP5 |
|||
| MBS692152-5x0025mg | MyBiosource | 5x0.025mg | EUR 1725 |
Human IGF-1 |
|||
| MBS691641-01mg | MyBiosource | 0.1mg | EUR 300 |
Human IGF-1 |
|||
| MBS691641-05mg | MyBiosource | 0.5mg | EUR 450 |
Human IGF-1 |
|||
| MBS691641-5x05mg | MyBiosource | 5x0.5mg | EUR 1725 |
Human IGF-2 |
|||
| MBS691655-001mg | MyBiosource | 0.01mg | EUR 300 |
Human IGF-2 |
|||
| MBS691655-005mg | MyBiosource | 0.05mg | EUR 450 |
Human IGF-2 |
|||
| MBS691655-5x005mg | MyBiosource | 5x0.05mg | EUR 1725 |
IGF-BP3, Human |
|||
| HY-P7020 | MedChemExpress | 10ug | EUR 280.8 |
IGF-BP5, Human |
|||
| HY-P7021 | MedChemExpress | 50ug | EUR 721.2 |
IGF-BP3, human |
|||
| RC216-12B3 | Bio Basic | 5ug | EUR 125.26 |
Anti-Human IGF-BP1 Antibody |
|||
| 101-M457 | ReliaTech | 100 µg | EUR 399 |
|
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. |
|||
Anti-Human IGF-BP2 Antibody |
|||
| 101-M458 | ReliaTech | 100 µg | EUR 399 |
|
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. |
|||
Anti-Human IGF-BP3 Antibody |
|||
| 101-M459 | ReliaTech | 100 µg | EUR 399 |
|
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. |
|||
Anti-Human IGF-BP5 Antibody |
|||
| 101-M461 | ReliaTech | 100 µg | EUR 399 |
|
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. |
|||
Anti-Human IGF-BP6 Antibody |
|||
| 101-M462 | ReliaTech | 100 µg | EUR 399 |
|
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. |
|||
Anti-Human IGF-BP7 Antibody |
|||
| 101-M463 | ReliaTech | 100 µg | EUR 399 |
|
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. |
|||
Anti-Human IGF-BP3 Antibody |
|||
| 102-P144 | ReliaTech | 100 µg | EUR 245.7 |
|
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. |
|||
Anti-Human IGF-BP5 Antibody |
|||
| 102-P232 | ReliaTech | 100 µg | EUR 245.7 |
|
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. |
|||
Anti-Human IGF-BP7 Antibody |
|||
| 102-P233 | ReliaTech | 100 µg | EUR 245.7 |
|
Description: The superfamily of insulin-like growth factor (IGF) binding proteins include the six high-affinity IGF binding proteins (IGFBP) and several low-affinity binding proteins referred to as IGFBP related proteins (IGFBP-rP). All IGFBP superfamily members are cysteine-rich proteins with conserved cysteine residues, which are clustered in the amino- and carboxy-terminal thirds of the molecule. IGFBPs modulate the biological activities of IGF proteins. Some IGFBPs may also have intrinsic bioactivity that is independent of their ability to bind IGF proteins. Post-translational modifications of IGFBP, including glycosylation, phosphorylation and proteolysis, have been shown to modify the affinities of the binding proteins to IGF. |
|||
IGF BP3 antibody |
|||
| 70R-IR022 | Fitzgerald | 50 ug | EUR 312 |
|
Description: Affinity purified Rabbit polyclonal IGF BP3 antibody |
|||
IGF BP5 antibody |
|||
| 70R-IR023 | Fitzgerald | 50 ug | EUR 312 |
|
Description: Affinity purified Rabbit polyclonal IGF BP5 antibody |
|||
IGF BP7 antibody |
|||
| 70R-IR024 | Fitzgerald | 50 ug | EUR 312 |
|
Description: Affinity purified Rabbit polyclonal IGF BP7 antibody |
|||
IGF BP7 antibody |
|||
| MBS535700-005mg | MyBiosource | 0.05mg | EUR 465 |
IGF BP7 antibody |
|||
| MBS535700-5x005mg | MyBiosource | 5x0.05mg | EUR 1945 |
IGF BP3 antibody |
|||
| MBS535722-005mg | MyBiosource | 0.05mg | EUR 465 |
IGF BP3 antibody |
|||
| MBS535722-5x005mg | MyBiosource | 5x0.05mg | EUR 1945 |
IGF BP5 antibody |
|||
| MBS535907-005mg | MyBiosource | 0.05mg | EUR 465 |
IGF BP5 antibody |
|||
| MBS535907-5x005mg | MyBiosource | 5x0.05mg | EUR 1945 |
IGF-1, Human |
|||
| HY-P7018 | MedChemExpress | 10ug | EUR 129.6 |
IGF-2, Human |
|||
| HY-P7019 | MedChemExpress | 100ug | EUR 432 |
IGF-1, human |
|||
| RC216-12 | Bio Basic | 1mg | EUR 451.5 |
IGF-1 (Human) |
|||
| MBS352114-1Bottle | MyBiosource | 1Bottle | EUR 350 |
IGF-1 (Human) |
|||
| MBS352114-5x1Bottle | MyBiosource | 5x1Bottle | EUR 1490 |
IGF-1 (Human) |
|||
| MBS352116-01mL | MyBiosource | 0.1mL | EUR 450 |
IGF-1 (Human) |
|||
| MBS352116-5x01mL | MyBiosource | 5x0.1mL | EUR 1950 |
IGF-2 (Human) |
|||
| MBS352118-1Bottle | MyBiosource | 1Bottle | EUR 350 |
IGF-2 (Human) |
|||
| MBS352118-5x1Bottle | MyBiosource | 5x1Bottle | EUR 1490 |
Recombinant Human LR3 IGF-I/IGF-1 |
|||
| PH2031-.01 | ApexBio | 10ug | EUR 208 |
|
Description: Peptides & Proteins|Recombinant Proteins |
|||
Recombinant Human LR3 IGF-I/IGF-1 |
|||
| PH2031-.1 | ApexBio | 10X10ug | EUR 496 |
|
Description: Peptides & Proteins|Recombinant Proteins |
|||
Anti-Human IGF-1 Antibody |
|||
| 101-M454 | ReliaTech | 100 µg | EUR 399 |
|
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity. |
|||
Anti-Human IGF-2 Antibody |
|||
| 101-M456 | ReliaTech | 100 µg | EUR 399 |
|
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity. |
|||
Anti-Human IGF-1 Antibody |
|||
| 102-P28 | ReliaTech | 100 µg | EUR 245.7 |
|
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity. |
|||
Anti-Human IGF-2 Antibody |
|||
| 102-P29 | ReliaTech | 100 µg | EUR 245.7 |
|
Description: Insulin-like growth factor (IGF)-I (also known as somatomedin C and somatomedin A) and IGF-II (multiplication stimulating activity or MSA) belong to the family of insulin-like growth factors that are structurally homologous to proinsulin. Mature IGF-I and IGF-II share approximately 70% sequence identity. Both IGF-I and IGF-II are expressed in many tissues and cell types and may have autocrine, paracrine and endocrine functions. Mature IGF-I and IGF-II are highly conserved between the human, bovine and porcine proteins (100% identity), and exhibit cross-species activity. |
|||
Antibody for Human IGF-1 |
|||
| SPC-699D-A565 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 565. |
|||
Antibody for Human IGF-1 |
|||
| SPC-699D-A633 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 633. |
|||
Antibody for Human IGF-1 |
|||
| SPC-699D-A655 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 655. |
|||
Antibody for Human IGF-1 |
|||
| SPC-699D-A680 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 680. |
|||
Antibody for Human IGF-1 |
|||
| SPC-699D-A700 | Stressmarq | 0.1mg | EUR 480 |
|
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to ATTO 700. |
|||
Antibody for Human IGF-1 |
|||
| SPC-699D-APCCY7 | Stressmarq | 0.1mg | EUR 565.2 |
|
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to APC/Cy7. |
|||
Antibody for Human IGF-1 |
|||
| SPC-699D-DY350 | Stressmarq | 0.1mg | EUR 496.8 |
|
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 350. |
|||
Antibody for Human IGF-1 |
|||
| SPC-699D-DY405 | Stressmarq | 0.1mg | EUR 483.6 |
|
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 405. |
|||
Antibody for Human IGF-1 |
|||
| SPC-699D-DY488 | Stressmarq | 0.1mg | EUR 471.6 |
|
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 488. |
|||
Antibody for Human IGF-1 |
|||
| SPC-699D-DY594 | Stressmarq | 0.1mg | EUR 474 |
|
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 594. |
|||
Antibody for Human IGF-1 |
|||
| SPC-699D-DY633 | Stressmarq | 0.1mg | EUR 468 |
|
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Dylight 633. |
|||
Antibody for Human IGF-1 |
|||
| SPC-699D-P594 | Stressmarq | 0.1mg | EUR 488.4 |
|
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to PE/ATTO 594. |
|||
Antibody for Human IGF-1 |
|||
| SPC-699D-STR | Stressmarq | 0.1mg | EUR 477.6 |
|
Description: A polyclonal antibody for IGF-1 from Human | Mouse. The antibody is produced in rabbit after immunization with human synthetic peptide from the mid-protein of Human IGF-1. The Antibody is tested and validated for WB, ICC/IF, IHC assays with the following recommended dilutions: WB (1:1000); ICC/IF (1:100); IHC (1:50). This IGF-1 antibody is conjugated to Streptavidin. |
|||
Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2) |
|||
| MBS635918-005mg | MyBiosource | 0.05mg | EUR 495 |
Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2) |
|||
| MBS635918-5x005mg | MyBiosource | 5x0.05mg | EUR 2075 |
Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2) |
|||
| MBS650945-001mg | MyBiosource | 0.01mg | EUR 390 |
Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2) |
|||
| MBS650945-005mg | MyBiosource | 0.05mg | EUR 540 |
Insulin-Like Growth Factor II, Recombinant, Human (Human IGF-II, IGF-II, IGFII, IGFII, IGF2, IGF-2, IGF 2) |
|||
| MBS650945-5x005mg | MyBiosource | 5x0.05mg | EUR 2275 |
Human IGF-I |
|||
| GWB-4FCE40 | GenWay Biotech | 0.1 mg | Ask for price |
Human IGF-I |
|||
| MBS400113-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Human IGF-I |
|||
| MBS400117-01mg | MyBiosource | 0.1mg | EUR 170 |
Human IGF-I |
|||
| MBS400117-05mg | MyBiosource | 0.5mg | EUR 235 |
Human IGF-I |
|||
| MBS400117-10mg | MyBiosource | 10mg | EUR 1595 |
Human IGF-I |
|||
| MBS400117-1mg | MyBiosource | 1mg | EUR 305 |
Human IGF-I |
|||
| MBS400117-5mg | MyBiosource | 5mg | EUR 940 |
Human Salivary IGF(salivary IGF) ELISA Kit |
|||
| QY-E05383 | Qayee Biotechnology | 96T | EUR 433.2 |
Human IGF-I / IGF-II Panel, Antigen Standard: Pre-Mixed |
|||
| SMX470 | Antigenix America | 2 Plex | EUR 150 |
IGF-I， Human |
|||
| E34M113H | EnoGene | 20 μg | EUR 155 |
|
Description: Recombinant Human Cytotoxic T-lymphocyte Protein 4 is produced by our Mammalian expression system and the target gene encoding Lys36-Asp161 is expressed with a Flag tag at the C-terminus. |
|||
IGF-I, Human |
|||
| MBS8575270-002mg | MyBiosource | 0.02mg | EUR 245 |
IGF-I, Human |
|||
| MBS8575270-5x002mg | MyBiosource | 5x0.02mg | EUR 940 |
IGF-II， Human |
|||
| E34M114H | EnoGene | 5 μg | EUR 155 |
IGF-II, Human |
|||
| MBS8575271-0005mg | MyBiosource | 0.005mg | EUR 245 |
IGF-II, Human |
|||
| MBS8575271-5x0005mg | MyBiosource | 5x0.005mg | EUR 940 |
Human IGF-1 LR3 |
|||
| SP-89927-100 | Alpha Diagnostics | 100 ug | EUR 270 |
Human IGF-1 LR3 |
|||
| MBS692296-02mg | MyBiosource | 0.2mg | EUR 300 |
Human IGF-1 LR3 |
|||
| MBS692296-1mg | MyBiosource | 1mg | EUR 450 |
Human IGF-1 LR3 |
|||
| MBS692296-5x1mg | MyBiosource | 5x1mg | EUR 1725 |
Związek między poziomami alarmin w surowicy a wskaźnikami specyficznymi dla choroby u pacjentów z zapaleniem naczyń związanym z cytoplazmatycznymi przeciwciałami przeciw neutrofilom
Background/purpose: We evaluated the connection between serum alarmin ranges and disease-specific indices in sufferers with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Sufferers and strategies: Sera and information from 79 sufferers had been utilized. For AAV-specific indices, Birmingham vasculitis exercise rating (BVAS), five-factor rating (FFS), and vasculitis harm index (VDI) had been collected and serum ranges of 4 alarmins (hepatoma-derived progress issue, excessive mobility group field protein 1, S100A9, and S100A12) had been measured utilizing enzyme-linked immunosorbent assay. Associations between alarmin ranges, AAV-specific indices, and inflammatory laboratory markers had been assessed.
Outcomes: S100A9 ranges had been considerably correlated with C-reactive protein ranges (r=0.316, p=0.005) and S100A12 ranges correlated with VDI (r=0.232, p=0.040), which was constant in a subgroup of sufferers with myeloperoxidase (perinuclear)-ANCA positivity. No different associations had been discovered between alarmin ranges and BVAS, FFS, and VDI.
Conclusion: The serum S100A12 degree was related to organ harm in AAV, particularly in myeloperoxidase (perinuclear)-ANCA-positive sufferers.
Zapalenie skórno-mięśniowe z dodatnim przeciwciałem anty-MDA5 z szybko postępującą śródmiąższową chorobą płuc: opis dwóch przypadków
Melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (DM) shows distinctive cutaneous and pathologic options. We describe two circumstances of myositis-associated quickly progressive interstitial lung illness (RP-ILD).
The sufferers had been two girls from Kerala, India. Each sufferers had anti-MDA5 antibody-positive myositis. Each sufferers offered with RP-ILD with none scientific options of myositis and succumbed to their sickness regardless of aggressive medical therapy. Anti-MDA5-antibody-positive DM is characterised by amyopathic illness with quickly progressive and deadly ILD.
Charakterystyka przeciwciał monoklonalnych przeciw tężcowi jako pierwszy krok w kierunku opracowania testu immunologicznego na siłę szczepionki in vitro
Batch launch testing for human and veterinary tetanus vaccines nonetheless depends closely on strategies that contain animals, notably for efficiency testing. The amount and high quality of tetanus antigen current in these merchandise is of utmost significance for product security and scientific impact. Immunochemical strategies that measure consistency of antigen content material and high quality, doubtlessly as an indicator of efficiency, may very well be a better option and negate the necessity for an in vivo efficiency check. These immunochemical strategies require at the least one nicely characterised monoclonal antibody (mAb) that’s particular for the goal antigen. On this paper we report the outcomes of the excellent characterisation of a panel of mAbs towards tetanus with a view to pick antibodies that can be utilized for improvement of an in vitro efficiency immunoassay.
We’ve assessed binding of the antibodies to native antigen (toxin), detoxified antigen (toxoid), adsorbed antigen and heat-altered antigen. Antibody perform was decided utilizing an in-house cell-based neutralisation assay to assist prior in vivo efficiency information that was obtainable for some, however not all, of the antibodies. As well as, antibody affinity was measured, and epitope competitors evaluation was carried out to establish pairs of antibodies that may very well be deployed in a sandwich immunoassay format. Not all characterisation assessments offered proof of “superiority” of 1 mAb over one other, however collectively the outcomes from all characterisation research allowed for choice of an antibody pair to be taken ahead to assay improvement.
Opis przypadku: autoimmunologiczne zapalenie mózgu związane z przeciwciałami dekarboksylazy kwasu przeciwglutaminowego: seria przypadków pediatrycznych
Background: Antibodies towards glutamic acid decarboxylase (GAD) are related to varied neurologic circumstances described in sufferers, together with stiff particular person syndrome, cerebellar ataxia, refractory epilepsy, and limbic and extralimbic encephalitis. There have been some case stories and investigations relating to anti-GAD65 antibody-associated encephalitis in grownup populations, however pediatric circumstances are uncommon. We retrospectively analyzed the scientific information of three anti-GAD65 antibody-positive sufferers to discover the range and scientific options of anti-GAD65 antibody-associated pediatric autoimmune encephalitis.
Strategies: The scientific information of a sequence of three sufferers optimistic for anti-GAD65 antibody had been retrospectively analyzed. GAD65 antibodies had been decided in serum and CSF utilizing a cell-based assay.
Outcomes: All three sufferers had been feminine, and the onset ages had been four years and 9 months, 6 years, and 16 years previous. Their scientific phenotypes included autoimmune limbic encephalitis, extralimbic encephalitis, and encephalitis combining limbic and extralimbic encephalitis. The scientific signs included seizures, reminiscence deficits, drowsiness, dysautonomia, and headache. All sufferers had irregular carinal MRI and EEG. All sufferers obtained immunotherapy and had transiently good responsiveness, however one affected person then skilled relapse. In follow-up, one affected person with extralimbic encephalitis recovered utterly, whereas two sufferers with limbic involvement had poor outcomes with refractory focal epilepsy.
Conclusion: Along with limbic encephalitis, extralimbic encephalitis can also be an necessary phenotype in sufferers who’re optimistic for anti-GAD65 antibodies. Early analysis and immunotherapy can enhance the signs. Nevertheless, sufferers with limbic encephalitis typically have refractory epilepsy within the continual section and have a poor long-term final result.
CXCL7 (48-109), Mouse |
|||
| MBS8575412-0005mg | MyBiosource | 0.005mg | EUR 245 |
CXCL7 (48-109), Mouse |
|||
| MBS8575412-5x0005mg | MyBiosource | 5x0.005mg | EUR 940 |
Mouse CXCL7 ELISA Kit |
|||
| MBS8291406-5x96Tests | MyBiosource | 5x96Tests | EUR 2755 |
Mouse CXCL7 ELISA Kit |
|||
| MBS8291406-96Tests | MyBiosource | 96Tests | EUR 620 |
Mouse Anti Human Neutrophil Activating Protein-2 (CXCL7) |
|||
| MBS140066-05mg | MyBiosource | 0.5mg | EUR 440 |
Mouse Anti Human Neutrophil Activating Protein-2 (CXCL7) |
|||
| MBS140066-1mg | MyBiosource | 1mg | EUR 600 |
Mouse Anti Human Neutrophil Activating Protein-2 (CXCL7) |
|||
| MBS140066-5x1mg | MyBiosource | 5x1mg | EUR 2375 |
Rat Monoclonal anti-mouse CXCL7 |
|||
| mAP-0211 | Angio Proteomie | 100ug | EUR 250 |
Anti-Human CXCL7 Antibody |
|||
| 101-M357 | ReliaTech | 100 µg | EUR 399 |
|
Description: NAP-2 or CXCL7 is a CXC chemokine that can signal through the CXCR1 and CXCR2 receptors. It is produced in leukocytes by enzymatic processing of a precursor called platelet basic protein (PBP). NAP-2 chemoattracts and activates neutrophils. Recombinant human NAP-2 protein is a 7.6 kDa protein containing 70 amino acid residues including the four highly conserved cysteine residues present in CXC chemokines, and also including the ELR motif common to CXC chemokines that bind to CXCR1 and CXCR2. |
|||
CXCL7 (PPBP) mouse monoclonal antibody, Azide Free |
|||
| PM1210P | Origene Technologies GmbH | 500 µg | Ask for price |
Mouse PPBP/CXCL7 PicoKine ELISA Kit |
|||
| EK0730 | BosterBio | 96 wells | EUR 510 |
|
Description: For Quantitative Detection of mouse CXCL7 in cell culture supernates, serum and plasma (heparin, EDTA). |
|||
Mouse PPBP/CXCL7 PicoKine ELISA Kit |
|||
| MBS1751073-5x96StripWells | MyBiosource | 5x96-Strip-Wells | EUR 2755 |
Mouse PPBP/CXCL7 PicoKine ELISA Kit |
|||
| MBS1751073-96StripWells | MyBiosource | 96-Strip-Wells | EUR 600 |
Mouse CXCL7/Thymus Chemokine-1 ELISA Kit |
|||
| E16ME0075 | EnoGene | 96T | EUR 833.33 |
Anti-Human NAP-2 (CXCL7) |
|||
| MBS550706-01mg | MyBiosource | 0.1mg | EUR 260 |
Anti-Human NAP-2 (CXCL7) |
|||
| MBS550706-02mg | MyBiosource | 0.2mg | EUR 335 |
Mouse beta Thromboglobulin (CXCL7/bTG) CLIA Kit |
|||
| 20-abx491403 | Abbexa |
|
|
Recombinant Mouse CXCL7 (40-113) protein(N-His)(active) |
|||
| PKSM041515-100ug | Elabscience Biotech | 100ug | EUR 739 |
|
Description: Mouse |
|||
Recombinant Mouse CXCL7 (40-113) protein(N-His)(active) |
|||
| PKSM041515-20ug | Elabscience Biotech | 20ug | EUR 249 |
|
Description: Mouse |
|||
Recombinant Mouse CXCL7 (48-109) protein(N-His)(active) |
|||
| PKSM041516-100ug | Elabscience Biotech | 100ug | EUR 739 |
|
Description: Mouse |
|||
Recombinant Mouse CXCL7 (48-109) protein(N-His)(active) |
|||
| PKSM041516-20ug | Elabscience Biotech | 20ug | EUR 249 |
|
Description: Mouse |
|||
Recombinant Mouse CXCL7 (40-113) protein (N-His)(active) |
|||
| MBS2569986-002mg | MyBiosource | 0.02mg | EUR 270 |
Recombinant Mouse CXCL7 (40-113) protein (N-His)(active) |
|||
| MBS2569986-01mg | MyBiosource | 0.1mg | EUR 690 |
Recombinant Mouse CXCL7 (40-113) protein (N-His)(active) |
|||
| MBS2569986-5x01mg | MyBiosource | 5x0.1mg | EUR 3105 |
Recombinant Mouse CXCL7 (48-109) protein (N-His)(active) |
|||
| MBS2569987-002mg | MyBiosource | 0.02mg | EUR 270 |
Recombinant Mouse CXCL7 (48-109) protein (N-His)(active) |
|||
| MBS2569987-01mg | MyBiosource | 0.1mg | EUR 690 |
Recombinant Mouse CXCL7 (48-109) protein (N-His)(active) |
|||
| MBS2569987-5x01mg | MyBiosource | 5x0.1mg | EUR 3105 |
Mouse CXC-Chemokine Ligand 7,CXCL7 ELISA KIT |
|||
| E2614Mo-1096T | Jiaxing Korain Biotech Ltd (BT Labs) | 10*96T | EUR 4122 |
Mouse CXC-Chemokine Ligand 7,CXCL7 ELISA KIT |
|||
| E2614Mo-48wells | Jiaxing Korain Biotech Ltd (BT Labs) | 48 wells | EUR 300 |
Mouse CXC-Chemokine Ligand 7,CXCL7 ELISA KIT |
|||
| E2614Mo-596T | Jiaxing Korain Biotech Ltd (BT Labs) | 5*96T | EUR 2061 |
Mouse CXC-Chemokine Ligand 7,CXCL7 ELISA KIT |
|||
| E2614Mo-96wells | Jiaxing Korain Biotech Ltd (BT Labs) | 96 wells | EUR 458 |
Mouse CXC-Chemokine Ligand 7, CXCL7 ELISA Kit |
|||
| MBS1603801-10x96StripWells | MyBiosource | 10x96-Strip-Wells | EUR 3955 |
Mouse CXC-Chemokine Ligand 7, CXCL7 ELISA Kit |
|||
| MBS1603801-48StripWells | MyBiosource | 48-Strip-Wells | EUR 305 |
Mouse CXC-Chemokine Ligand 7, CXCL7 ELISA Kit |
|||
| MBS1603801-5x96StripWells | MyBiosource | 5x96-Strip-Wells | EUR 2005 |
Mouse CXC-Chemokine Ligand 7, CXCL7 ELISA Kit |
|||
| MBS1603801-96StripWells | MyBiosource | 96-Strip-Wells | EUR 475 |
Mouse CXC-Chemokine Ligand 7, CXCL7 GENLISA ELISA |
|||
| KLM2614 | Krishgen | 1 x 96 wells | EUR 341 |
Anti-Human NAP-2 (CXCL7) Antibody |
|||
| 101-M81 | ReliaTech | 500 µg | EUR 246.75 |
|
Description: NAP-2 is a CXC chemokine that can signal through the CXCR1 and CXCR2 receptors. It is produced in leukocytes by enzymatic processing of a precursor called platelet basic protein (PBP). NAP-2 chemoattracts and activates neutrophils. Recombinant human NAP-2 protein is a 7-8 kDa protein containing 70 amino acid residues including the four highly conserved cysteine residues present in CXC chemokines, and also including the ELR motif common to CXC chemokines that bind to CXCR1 and CXCR2. |
|||
Anti-Human NAP-2 (CXCL7) Antibody |
|||
| 102-P191G | ReliaTech | 100 µg | EUR 245.7 |
|
Description: Neutrophil Activating Peptide 2 (NAP2), Connective Tissue Activating Protein III (CTAPIII) and βthrombogulin ( βTG), are proteolytically processed carboxylterminal fragments of platelet basic protein (PBP) which is found in the alphagranules of human platelets. NAP2 is a member of the CXC chemokines. Similar to other ELR domain containing CXC chemokines such as IL8 and the GRO proteins, NAP2 has been shown to bind CXCR2 and to chemoattract and activate neutrophils. Although CTAPIII, βTG and PBP represent aminoterminal extended variants of NAP 2 and possess the same CXC chemokine domains, these proteins do not exhibit NAP2 activity. It has been shown that the additional aminoterminal residues of CTAP III masks the critical ELR receptor binding domain that is exposed on NAP2 and may account for lack of NAP2 activity. |
|||
Anti-Human NAP-2 (CXCL7) Antibody |
|||
| 102-P71 | ReliaTech | 100 µg | EUR 245.7 |
|
Description: NAP-2 is a CXC chemokine that can signal through the CXCR1 and CXCR2 receptors. It is produced in leukocytes by enzymatic processing of a precursor called platelet basic protein (PBP). NAP-2 chemoattracts and activates neutrophils. Recombinant human NAP-2 protein is a 7-8 kDa protein containing 70 amino acid residues including the four highly conserved cysteine residues present in CXC chemokines, and also including the ELR motif common to CXC chemokines that bind to CXCR1 and CXCR2. |
|||
Mouse Pro-Platelet Basic Protein (CXCL7) ELISA Kit |
|||
| IMSPPBPKT | Innovative research | each | EUR 702 |
|
Description: Mouse Pro-Platelet Basic Protein (CXCL7) ELISA Kit |
|||
Mouse Pro-Platelet Basic Protein (CXCL7) ELISA Kit |
|||
| MBS8420837-1Kit | MyBiosource | 1Kit | EUR 755 |
Mouse Pro-Platelet Basic Protein (CXCL7) ELISA Kit |
|||
| MBS8420837-5x1Kit | MyBiosource | 5x1Kit | EUR 3455 |
CXCL7/PBP Antibody |
|||
| DF6695 | Affbiotech | 200ul | EUR 420 |
CXCL7/PBP Antibody |
|||
| DF6695-100ul | Affinity Biosciences | 100ul | EUR 280 |
CXCL7/PBP Antibody |
|||
| DF6695-200ul | Affinity Biosciences | 200ul | EUR 350 |
CXCL7 Protein, Mouse, Recombinant (aa 40-113, His Tag) |
|||
| MBS8122558-005mg | MyBiosource | 0.05mg | EUR 395 |
CXCL7 Protein, Mouse, Recombinant (aa 40-113, His Tag) |
|||
| MBS8122558-5x005mg | MyBiosource | 5x0.05mg | EUR 1635 |
Human CXCL7 Antibody |
|||
| 32852-05111 | AssayPro | 150 ug | EUR 215 |
Anti-Human PPBP/CXCL7/NAP-2 Antibody |
|||
| MBS1569895-01mg | MyBiosource | 0.1mg | EUR 375 |
Anti-Human PPBP/CXCL7/NAP-2 Antibody |
|||
| MBS1569895-5x01mg | MyBiosource | 5x0.1mg | EUR 1390 |
CXCL7，Human |
|||
| E34M164H | EnoGene | 5 μg | EUR 155 |
CXCL7, Human |
|||
| MBS8575321-0005mg | MyBiosource | 0.005mg | EUR 245 |
CXCL7, Human |
|||
| MBS8575321-5x0005mg | MyBiosource | 5x0.005mg | EUR 940 |
Mouse βTG/PBP/CXCL7/NAP2(Thromboglobulin, Beta) ELISA Kit |
|||
| RE3404M-48wells | Reed Biotech | 48 wells | EUR 116.55 |
Mouse βTG/PBP/CXCL7/NAP2(Thromboglobulin, Beta) ELISA Kit |
|||
| RE3404M-96wells | Reed Biotech | 96 wells | EUR 161.55 |
Mouse βTG/PBP/CXCL7/NAP2(Thromboglobulin, Beta) ELISA Kit |
|||
| RE3404M-48wellsplate | Reed Biotech | 48-wells plate | EUR 126 |
Mouse βTG/PBP/CXCL7/NAP2(Thromboglobulin, Beta) ELISA Kit |
|||
| RE3404M-96wellsplate | Reed Biotech | 96-wells plate | EUR 180 |
Mouse βTG/PBP/CXCL7/NAP2(Thromboglobulin, Beta) ELISA Kit |
|||
| SYP-M0280-48wellsplate | UpingBio | 48 wells plate | EUR 180 |
Mouse βTG/PBP/CXCL7/NAP2(Thromboglobulin, Beta) ELISA Kit |
|||
| SYP-M0280-96wellsplate | UpingBio | 96 wells plate | EUR 220 |
Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit |
|||
| E-EL-M1269-24Tests | Elabscience Biotech | 24 Tests | EUR 150 |
|
Description: Sandwich |
|||
Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit |
|||
| E-EL-M1269-48Tests | Elabscience Biotech | 48 Tests | EUR 487 |
|
Description: Sandwich |
|||
Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit |
|||
| E-EL-M1269-96Tests | Elabscience Biotech | 96 Tests | EUR 609 |
|
Description: Sandwich |
|||
Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit |
|||
| E-EL-M1269-96Tests10 | Elabscience Biotech | 96 Tests *10 | EUR 6090 |
|
Description: Sandwich |
|||
Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit |
|||
| E-EL-M1269-96Tests5 | Elabscience Biotech | 96 Tests *5 | EUR 3045 |
|
Description: Sandwich |
|||
Sheep Polyclonal anti-Human CXCL7 (NAP-2) |
|||
| hAP-5825 | Angio Proteomie | 50ug | EUR 400 |
ELISA kit for Mouse ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) |
|||
| E-EL-M1269 | Elabscience Biotech | 1 plate of 96 wells | EUR 640.8 |
|
Description: A sandwich ELISA kit for quantitative measurement of Mouse ?TG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) in samples from Serum, Plasma, Cell supernatant |
|||
NAP-2 Antibody / CXCL7 |
|||
| R31872 | NSJ Bioreagents | 100 ug | EUR 356.15 |
|
Description: Chemokine (C-X-C motif) ligand 7 (CXCL7), also known as NAP-2 or Pro-Platelet basic protein (PPBP), is a human gene. The protein encoded by this gene is a platelet-derived growth factor that belongs to the CXC chemokine family. This growth factor is a potent chemoattractant and activator of neutrophils. It has been shown to stimulate various cellular processes including DNA synthesis, mitosis, glycolysis, intracellular cAMP accumulation, prostaglandin E2 secretion, and synthesis of hyaluronic acid and sulfated glycosaminoglycan. It also stimulates the formation and secretion of plasminogen activator by synovial cells. Furthermore, the protein is an antimicrobial protein with bactericidal and antifungal activity. |
|||
Mouse Chemokine (C-X-C motif) ligand 7 ( CXCL7) ELISA Kit |
|||
| EKN43824-48T | Biomatik Corporation | 48T | EUR 350.42 |
Mouse Chemokine (C-X-C motif) ligand 7 ( CXCL7) ELISA Kit |
|||
| EKN43824-5x96T | Biomatik Corporation | 5x96T | EUR 2377.85 |
Mouse Chemokine (C-X-C motif) ligand 7 ( CXCL7) ELISA Kit |
|||
| EKN43824-96T | Biomatik Corporation | 96T | EUR 500.6 |
Mouse Chemokine (C-X-C motif) ligand 7 ( CXCL7) ELISA Kit |
|||
| EKU02713-48T | Biomatik Corporation | 48T | EUR 514.08 |
Mouse Chemokine (C-X-C motif) ligand 7 ( CXCL7) ELISA Kit |
|||
| EKU02713-5x96T | Biomatik Corporation | 5x96T | EUR 3488.4 |
Mouse Chemokine (C-X-C motif) ligand 7 ( CXCL7) ELISA Kit |
|||
| EKU02713-96T | Biomatik Corporation | 96T | EUR 734.4 |
CXCL7/NAP-2 |
|||
| PR27118 | Neuromics | 2 ug | EUR 229.2 |
CXCL7/NAP-2 |
|||
| PR27118-B | Neuromics | each | EUR 184.5 |
Uncoated Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit |
|||
| E-UNEL-M0083-24Tests | Elabscience Biotech | 24 Tests | Ask for price |
|
Description: Sandwich |
|||
Uncoated Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit |
|||
| E-UNEL-M0083-48Tests | Elabscience Biotech | 48 Tests | EUR 958 |
|
Description: Sandwich |
|||
Uncoated Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit |
|||
| E-UNEL-M0083-96Tests | Elabscience Biotech | 96 Tests | EUR 399 |
|
Description: Sandwich |
|||
Uncoated Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit |
|||
| E-UNEL-M0083-96Tests10 | Elabscience Biotech | 96 Tests *10 | EUR 3990 |
|
Description: Sandwich |
|||
Uncoated Mouse βTG/PBP/CXCL7/NAP2-Thromboglobulin, Beta- ELISA Kit |
|||
| E-UNEL-M0083-96Tests5 | Elabscience Biotech | 96 Tests *5 | EUR 1995 |
|
Description: Sandwich |
|||
Human NAP2(CXCL7) |
|||
| 90222-A | BPS Bioscience | 2 µg | EUR 130 |
|
Description: Recombinant NAP-2 is a disulfide-linked monomeric protein consisting of 71 amino acid residues and migrates as an approximately 8 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human NAP-2 (CXCL7) mature chain was expressed in E. coli. |
|||
Human NAP2(CXCL7) |
|||
| 90222-B | BPS Bioscience | 10 µg | EUR 205 |
|
Description: Recombinant NAP-2 is a disulfide-linked monomeric protein consisting of 71 amino acid residues and migrates as an approximately 8 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE. Optimized DNA sequence encoding Human NAP-2 (CXCL7) mature chain was expressed in E. coli. |
|||
CXCL7 Rabbit pAb |
|||
| E2160414 | EnoGene | 100ul | EUR 225 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
Uncoated Mouse betaTG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) ELISA Kit |
|||
| MBS2571903-15x96Tests3xMBS2571967AncillaryKit | MyBiosource | 15x96Tests+3xMBS2571967(AncillaryKit) | EUR 1565 |
Uncoated Mouse betaTG/PBP/CXCL7/NAP2 (Thromboglobulin, Beta) ELISA Kit |
|||
| MBS2571903-5x96TestsMBS2571967AncillaryKit | MyBiosource | 5x96Tests+MBS2571967(AncillaryKit) | EUR 670 |
Mouse Ppbp/Cxcl7 (Chemokine subfamily B Cys-X-Cys) ELISA Kit |
|||
| MBS7615137-10x96StripWells | MyBiosource | 10x96-Strip-Wells | EUR 3900 |
Mouse Ppbp/Cxcl7 (Chemokine subfamily B Cys-X-Cys) ELISA Kit |
|||
| MBS7615137-48StripWells | MyBiosource | 48-Strip-Wells | EUR 340 |
Mouse Ppbp/Cxcl7 (Chemokine subfamily B Cys-X-Cys) ELISA Kit |
|||
| MBS7615137-5x96StripWells | MyBiosource | 5x96-Strip-Wells | EUR 2045 |
Mouse Ppbp/Cxcl7 (Chemokine subfamily B Cys-X-Cys) ELISA Kit |
|||
| MBS7615137-96StripWells | MyBiosource | 96-Strip-Wells | EUR 455 |
Recombinant Rat CXCL7 |
|||
| MBS7611197-005mg | MyBiosource | 0.05mg | EUR 345 |
